EpimAb Biotherapeutics Strengthens Scientific Advisory Board with Addition of Professor Mark Smyth
SHANGHAI, China--(BUSINESS WIRE)-- EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, today announced the appointment of Professor Mark Smyth to the company’s Scientific Advisory Board. Currently a Senior Scientist and the Immunology Department Coordinator at QIMR Berghofer Medical Research Institute, Professor Smyth brings over 20 years of immuno-oncology expertise and research experience to the Scientific Advisory Board.
“We are very proud to welcome Professor Smyth to EpimAb’s Scientific Advisory Board,” said Dr. Chengbin Wu, CEO and founder of EpimAb. “As a worldwide leader in immuno-oncology research he will be able to significantly contribute to EpimAb’s rapidly increasing portfolio of I/O-bispecifics. We have been working closely with the lab of Professor Smyth as part of our recently announced research collaboration with QIMR Berghofer to identify novel target combinations.”
“The field of bispecifics brings a promising new approach to immuno-oncology and EpimAb’s FIT-Ig® technology could help to unlock new areas in this field,” said Professor Smyth. “I have been following the rapid progress of EpimAb’s portfolio for a few years and look forward to continuing to work alongside the team at EpimAb to help further their portfolio of I/O bispecifics.”
Professor Smyth is the highest-cited immunologist in Australia and has been a worldwide leader in cancer immune surveillance over the last 20 years. He completed his Ph.D. at the University of Melbourne’s Department of Pathology in 1988 and trained at the NCI for four years before commencing his independent research career in Australia. During his career, Professor Smyth has defined immune-mediated dormancy of cancer and the role of the host in chemotherapy and targeted therapy responses in mice and humans. More recently, Professor Smyth provided new means of classifying natural killer cell subtypes and two new targets for cancer immunotherapy. He is a past winner of the Coley Medal and Brupbacher Foundation Prizes in Cancer Research.
About EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company with research and manufacturing facilities in Shanghai and Suzhou with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform and pipeline assets to partners worldwide. For further information, please visit www.epimab.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200723005978/en/
Source: EpimAb Biotherapeutics
View this news release online at: